Sermorelin History & Development: From Peptide Discovery to Compounding Pharmacy

The Science Behind GHRH: Why Sermorelin Exists

Sermorelin's entire rationale depends on understanding what growth hormone-releasing hormone does in normal physiology. The hypothalamus releases GHRH in discrete pulses, primarily at night, to drive the pituitary's somatotroph cells to produce and secrete growth hormone (GH). GH then stimulates the liver and peripheral tissues to produce insulin-like growth factor 1 (IGF-1), which mediates most of GH's anabolic and metabolic effects.

By the 1970s, researchers suspected that many cases of short stature and adult GH deficiency were not caused by a broken pituitary, but by insufficient hypothalamic GHRH drive. That single hypothesis drove two decades of peptide chemistry work and eventually produced sermorelin.

The Endogenous GHRH Molecule

Full-length endogenous GHRH contains 44 amino acids. Researchers at the Salk Institute and the Guillemin laboratory, working independently from groups at the Rivier and Vale laboratories, established that the first 29 amino acids of GHRH are sufficient to fully activate the GHRH receptor and stimulate GH secretion [1]. This truncated sequence became the pharmacological template for sermorelin.

The GHRH receptor itself is a G-protein-coupled receptor expressed on pituitary somatotrophs. Binding of GHRH (or sermorelin) activates adenylyl cyclase, raises intracellular cAMP, and triggers both immediate GH exocytosis and longer-term transcription of the GH gene [2]. Because the receptor is the same one used by endogenous GHRH, sermorelin produces a physiological GH pulse rather than the supraphysiological flat-line elevation associated with exogenous recombinant GH.

Why Physiological Pulsatility Matters Clinically

Endogenous GH is secreted in 6 to 12 discrete pulses per 24 hours in healthy adults, with the largest pulse occurring 60 to 90 minutes after sleep onset [3]. Recombinant human GH (rhGH), injected once daily, creates a single pharmacological peak that does not replicate this rhythm. Sermorelin, by contrast, amplifies the pituitary's existing pulse-generation machinery. The pituitary's own negative-feedback systems remain intact, so IGF-1 elevation feeds back to suppress further GH release. This built-in brake is frequently cited as a safety advantage over exogenous rhGH, though no head-to-head long-term safety trial has been completed to quantify that difference in adults.

Isolation of GHRH: The 1982 Breakthrough

The isolation of GHRH as a defined molecular entity came from an unexpected source: pancreatic tumors. Two groups simultaneously reported in 1982 that ectopic GHRH secreted by pancreatic islet cell tumors caused acromegaly in affected patients. Guillemin's group at the Salk Institute and Rivier's group at the same institution purified GHRH from a pancreatic tumor specimen and sequenced the full 44-amino-acid peptide, publishing in Science in July 1982 [4].

Within months, the same groups demonstrated that GHRH(1-29)-NH2, the first 29 residues with an amide terminus, retained full receptor-binding affinity and GH-stimulating potency in animal and early human studies. This truncated molecule is sermorelin. The amide terminus at position 29 protects the peptide from carboxypeptidase degradation and extends its biological half-life modestly compared with the linear fragment.

From Laboratory Peptide to Investigational Drug

Between 1982 and the early 1990s, sermorelin moved through investigational new drug (IND) studies focused primarily on its use as a diagnostic provocative test for GH secretory reserve. Physicians could administer a 1 mcg/kg intravenous bolus and measure peak serum GH at 15, 30, 45, and 60 minutes. A peak GH response below 5 ng/mL indicated pituitary insufficiency; a response above 10 ng/mL suggested intact somatotroph function [5]. This diagnostic application built the early clinical database and made sermorelin familiar to pediatric endocrinologists before any therapeutic indication existed.

Serono's Therapeutic Development Program

Serono Laboratories (now Merck KGaA/EMD Serono) acquired the commercial rights to sermorelin acetate and pursued a therapeutic indication for pediatric growth hormone deficiency. Their clinical development program focused on growth velocity as the primary endpoint, which the FDA accepted because height gain is objective and clinically meaningful in children with confirmed GHD.

Walker et al. 1990: The Trial That Built the Therapeutic Case

The most cited efficacy study from the therapeutic development program is Walker et al., published in Pediatrics in 1990 [6]. The trial enrolled 167 children with idiopathic growth hormone deficiency and compared subcutaneous sermorelin 30 mcg/kg/day administered nightly against placebo over 6 months, with an open-label extension.

Primary Efficacy Findings

Children receiving sermorelin showed a statistically significant increase in annualized height velocity compared with placebo (P<0.001). Mean height velocity increased from approximately 3.7 cm/year at baseline to 7.5 cm/year after 6 months of treatment, representing a near-doubling of growth rate. Placebo-treated children showed no significant change in growth velocity over the same period [6].

Serum IGF-1 levels rose significantly in the sermorelin group, consistent with increased pituitary GH output driving hepatic IGF-1 production. Bone age advancement was not accelerated beyond what would be expected from growth normalization, a finding that distinguished sermorelin favorably from higher-dose rhGH regimens in some earlier comparisons.

Safety Data From Walker et al.

Adverse events were mild and injection-site related. No cases of glucose intolerance, intracranial hypertension, or slipped capital femoral epiphysis were reported during the 6-month controlled phase [6]. These findings supported the FDA's eventual approval, though the trial's 6-month primary endpoint left longer-term safety questions that subsequent open-label data only partially addressed.

The Walker 1990 data can be read through a framework that distinguishes between two clinical questions that often get conflated: (1) Does sermorelin raise GH and IGF-1? (Answer: yes, consistently.) (2) Does that rise translate to clinically meaningful final adult height in GHD children? The 6-month trial answered question one compellingly but could not answer question two. Longer follow-up data from open-label extensions suggested continued growth benefit, but no randomized controlled trial ever completed a full assessment to final adult height using sermorelin alone.

FDA Approval in 1997 and Voluntary Withdrawal in 2002

The FDA approved sermorelin acetate (brand name Geref) on December 30, 1997, under NDA 020040, for the treatment of idiopathic growth hormone deficiency in children with growth failure [7]. The approval was for subcutaneous injection at 30 mcg/kg/day administered once nightly.

Geref's approval came during a period when recombinant human GH had already become firmly established as the standard of care for pediatric GHD. Rhizopus-derived biosynthetic GH had been available since 1985, and by 1997 multiple rhGH products competed for the pediatric market. Sermorelin occupied a niche: it was less expensive than rhGH, mechanistically distinct, and appealing to practitioners who favored stimulating endogenous GH over replacing it.

Why Serono Withdrew Geref

Serono voluntarily withdrew Geref from the U.S. Market in 2002. The company did not cite safety concerns as the reason for withdrawal. The stated rationale was commercial: the pediatric GHD market was dominated by rhGH products, and Geref could not compete profitably given the manufacturing costs of a peptide drug against the established market position of recombinant GH products like Genotropin, Humatrope, and Nutropin.

The FDA's drug withdrawal database lists Geref as voluntarily discontinued, not withdrawn for safety or efficacy reasons [7]. This distinction matters because it means the underlying NDA data are not invalidated. The compound's mechanism, pharmacology, and safety profile remain scientifically intact; the product simply no longer has a commercial sponsor willing to maintain the NDA.

The Transition to 503A Compounding

After Geref's withdrawal, compounding pharmacies operating under Section 503A of the Food, Drug, and Cosmetic Act began producing sermorelin acetate as a prescription compounded preparation. Section 503A allows licensed pharmacies to compound drugs for individual patients based on a valid prescription from a licensed practitioner, even when no commercially available FDA-approved product exists [8].

Sermorelin's transition into compounding was rapid, driven partly by its relatively straightforward peptide chemistry and partly by growing off-label interest in adult GH axis modulation. By the mid-2000s, sermorelin had migrated from a pediatric endocrinology drug to a compound used by anti-aging and functional medicine practitioners for adult patients with low IGF-1, fatigue, body composition concerns, and sleep disturbances.

Mechanism of Action: Molecular and Clinical Depth

Sermorelin's mechanism begins at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor encoded by the GHRHR gene on chromosome 7p14 [2]. Mutations in this gene cause autosomal recessive isolated GHD, confirming that the GHRH-GHRHR axis is not redundant but essential for normal GH secretion.

Receptor Binding and Signal Transduction

When sermorelin binds GHRHR, the receptor couples to the stimulatory G-protein (Gs), activating adenylyl cyclase and raising intracellular cyclic AMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates ion channels and transcription factors in the somatotroph. The immediate result is calcium influx and GH vesicle exocytosis. The delayed result is increased transcription of the GH1 gene, meaning sustained sermorelin dosing may increase the somatotroph's capacity to produce GH over weeks to months [2].

Somatostatin, the hypothalamic GH-inhibiting hormone, acts as a physiological antagonist at a separate receptor on the somatotroph. Sermorelin does not block somatostatin signaling, so the normal inhibitory tone remains functional. This is the mechanistic basis for the claim that sermorelin preserves physiological feedback regulation.

Pharmacokinetics After Subcutaneous Injection

After subcutaneous injection, sermorelin is absorbed with a time-to-peak serum concentration (Tmax) of approximately 10 to 20 minutes. The elimination half-life is short, on the order of 10 to 20 minutes, because serine proteases and dipeptidyl peptidases cleave the peptide rapidly in plasma and at the injection site [9]. The brief half-life means GH secretion returns to baseline within 1 to 2 hours after injection, preserving the pulsatile pattern rather than sustaining an artificially elevated plateau.

Peak serum GH after a 30 mcg/kg subcutaneous dose in adults typically appears at 20 to 40 minutes post-injection and may reach 10 to 30 ng/mL depending on age, body composition, and baseline somatotroph reserve. IGF-1 rises more slowly over days to weeks of nightly dosing because hepatic IGF-1 production responds to the integrated GH signal rather than individual peaks.

Age-Related Decline in GHRH Drive

The age-related decline in GH secretion is well documented. Mean 24-hour GH secretion falls by approximately 14% per decade after age 30 in healthy adults [3]. Studies using deconvolution analysis of serial GH measurements have shown that this decline is driven primarily by reduced pulse amplitude rather than reduced pulse frequency, and that the pituitary retains somatotroph capacity throughout life. The implication is that the age-related GH decline may reflect diminishing hypothalamic GHRH drive rather than primary pituitary failure, which is the physiological argument for GHRH-analog therapy in older adults [3].

Adult Off-Label Use: Evidence and Limitations

Adult use of sermorelin is off-label. No randomized controlled trial comparable in size to STEP-1 for semaglutide has evaluated sermorelin in adult populations over durations sufficient to assess body composition or clinical outcomes with confidence. The evidence base consists of smaller mechanistic studies, open-label cohorts, and extrapolation from GHRH physiology.

Body Composition and Metabolic Effects

A randomized, double-blind, placebo-controlled trial by Vittone et al. Examined GHRH analog effects on body composition in older men and found modest reductions in fat mass and increases in lean mass over 6 months of treatment, with no significant adverse metabolic effects [10]. The effect sizes were smaller than those seen with exogenous rhGH and require replication in larger cohorts.

GH and IGF-1 influence glucose metabolism. GH is counter-regulatory to insulin, and supraphysiological GH levels impair insulin sensitivity. Sermorelin, by stimulating GH within a physiological range, is less likely to cause insulin resistance than pharmacological rhGH doses, but patients with pre-existing glucose intolerance or type 2 diabetes still warrant careful monitoring of fasting glucose and HbA1c during treatment.

Sleep Architecture Effects

GH secretion is tightly linked to slow-wave sleep (SWS). The largest GH pulse of the 24-hour period occurs during the first bout of SWS, and GHRH itself appears to promote SWS when administered centrally in animal models [11]. Some practitioners report that patients taking nightly sermorelin describe subjective improvements in sleep quality. Objective polysomnographic data in humans given sermorelin specifically are limited, and no published randomized trial has assessed sleep architecture as a primary endpoint.

Current Prescribing Context

Sermorelin is prescribed today by physicians in functional medicine, anti-aging medicine, and some endocrinology practices for adult patients with low-normal or below-normal IGF-1, documented fatigue, poor body composition despite adequate lifestyle intervention, or confirmed adult-onset GHD where the patient prefers a pituitary-stimulating approach over exogenous rhGH. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults notes that GHRH analogs stimulate endogenous GH secretion and that serum IGF-1 is the recommended monitoring parameter, targeting an age-adjusted IGF-1 in the upper half of the normal range [12].

The guideline states: "We recommend against GH treatment in patients with active malignancy" [12]. This contraindication applies equally to sermorelin given its mechanism of raising IGF-1, a known mitogen.

Regulatory Trajectory and the 2023 FDA Peptide Guidance

The FDA's authority over compounded peptides has evolved since Geref's withdrawal. In October 2023, the FDA issued guidance clarifying that certain bulk drug substances, including some peptides, may not be used in 503A compounding because they have not been evaluated for safety and effectiveness in compounding contexts [8]. Sermorelin's status under this guidance has been a point of active discussion among compounding pharmacies, as it appears on the FDA's list of bulk drug substances currently under review rather than on the prohibited list, meaning it remains available through 503A pharmacies as of early 2025 pending final agency determination.

Practitioners and patients should verify current regulatory status directly with their compounding pharmacy and consult FDA communications, as this area of regulation is changing.

Dosing Principles Derived From the Development History

The 30 mcg/kg/day dose used in Walker et al. [6] was established in pediatric patients. Adult dosing in compounding practice generally ranges from 200 to 500 mcg per injection administered subcutaneously, typically in the abdomen or thigh, once nightly at bedtime. Nightly administration aligns sermorelin's GH-stimulating action with the natural sleep-associated GH surge, theoretically amplifying the physiological pulse rather than creating an off-rhythm peak.

Monitoring typically includes baseline and 3-month serum IGF-1, fasting glucose, and a symptom review. If IGF-1 remains below the age-adjusted mid-normal range at 3 months and the patient tolerates treatment, dose titration upward by 100 mcg increments is a common clinical approach, though this practice is not derived from randomized trial data.